A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Jun 2018
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Carboplatin; Docetaxel; Pertuzumab; Trastuzumab
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms KRISTINE
- Sponsors Roche
- 22 Jun 2018 This trial has been completed in Belgium (End date: 2018-05-29), according to European Clinical Trials Database.
- 29 May 2018 This trial has been completed in Spain on 30-Apr-2018, according to European Clinical Trials Database.
- 25 Apr 2018 Planned End Date changed from 31 Mar 2018 to 31 May 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History